CONSHOHOCKEN, Pa., Feb. 28, 2025 /PRNewswire/ -- The GBS | CIDP Foundation International today released new survey data illustrating how people with Guillain-Barré Syndrome experience this ...
Everyday Health on MSN
What’s the difference between chronic inflammatory demyelinating polyneuropathy and Guillain-Barré syndrome?
Learn the key differences between CIDP and GBS, including causes, onset, and treatments, to ensure you get the correct diagnosis.
Guillain-Barré Syndrome (GBS) is a rare neuromuscular condition that can cause rapid paralysis. Diagnosing GBS is challenging, and misdiagnosis can lead to delayed treatment and potentially long-term ...
This week, we are going to continue down the road of autoimmune peripheral nerve conditions to discuss two that we have touched on in the past—Guillain-Barré Syndrome and CIDP (chronic inflammatory ...
Previously we have discussed neuropathy in the context of diabetic neuropathy, back-related neuropathies and the like. However, this week we are going to discuss an autoimmune neuropathy called ...
Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy that can lead to severe weakness of the limbs, face, and respiratory muscles. Its pathophysiology involves autoantibodies that attack ...
Real-world evidence study shows ANX005 improves muscle strength and functional outcomes in Guillain-Barré Syndrome compared to current treatments. Potential regulatory concerns may arise if the FDA ...
Biopharmaceutical company Annexon (ANNX) is showing promising results in developing treatments for inflammatory-related diseases. Its flagship candidate, ANX005, showed positive topline Phase 3 data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results